 Germany-based Boehringer Ingelheim has accepted Dicerna Pharmaceuticals Incs NASDAQ: DRNA GalXC RNAi candidate for advancement under the existing agreement between the companies to discover and develop novel therapies for the treatment of chronic liver diseases. Dubbed DCR-LIV2, the compound will be investigated for the treatment of nonalcoholic steatohepatitis NASH. 